{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:22:09Z","timestamp":1794280929349,"version":"4.9.0"},"reference-count":134,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/14787210.2021.1935237","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T17:36:13Z","timestamp":1621964173000},"page":"53-69","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":47,"title":["Carbapenemase producing <i>Klebsiella pneumoniae<\/i>: implication on future therapeutic strategies"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0239","authenticated-orcid":false,"given":"Ilias","family":"Karaiskos","sequence":"first","affiliation":[{"name":"1st Department of Internal Medicine - Infectious Diseases, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-9848","authenticated-orcid":false,"given":"Irene","family":"Galani","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, University General Hospital ATTIKON, National and Kapodistrian University of Athens, Faculty of Medicine, Infectious Diseases Laboratory, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Papoutsaki","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamprini","family":"Galani","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine - Infectious Diseases, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-5065","authenticated-orcid":false,"given":"Helen","family":"Giamarellou","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine - Infectious Diseases, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"cit0001","unstructured":"Centers for Disease Control and Prevention (CDC). Antimicrobial resistance threats report. 2019. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf"},{"key":"cit0002","unstructured":"World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. [cited 2021 Feb 01]. Available from: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz824"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30755-8"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01882-17"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa431"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12697"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.08.030"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.914172"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00151"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa497"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00115-20"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1563071"},{"key":"cit0016","unstructured":"Global Antibiotic Research and Development Partnership (GARDP). Medicines Patent Pool (MPP) and World Health Organization (WHO). Delivering on the sustainable access of antibiotics: moving from principles to practice workshop report. 2019. Available from: https:\/\/gardp.org\/uploads\/2019\/10\/GARDP-access-workshop-report-2019.pdf"},{"key":"cit0017","unstructured":"Rex JH, Outterson K New antibiotics are not being registered or sold in Europe in a timely manner. 2020. [cited 2021 Jan 30]. Available from: https:\/\/amr.solutions\/2020\/09\/07\/new-antibiotics-are-not-being-registered-or-sold-in-europe-in-a-timely-manner"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-020-0285-z"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2856-2861.2001"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2013.02.001"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2017.11.002"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00001-07"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01076-18"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12719"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"cit0026","author":"Hansen GT","year":"2021","journal-title":"Infect Dis Ther"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx148"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02729-16"},{"key":"cit0030","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","volume":"20","author":"Albiger B","year":"2015","journal-title":"Euro Surveill"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/249856"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239308"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0902-x"},{"key":"cit0034","first-page":"dkaa504","author":"Sader HS","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"cit0035","first-page":"dkaa511","author":"Isler B","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02596-17"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106111"},{"key":"cit0038","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","author":"CLSI. Clinical &amp; Laboratory Standards Institute","year":"2020","edition":"30"},{"key":"cit0039","unstructured":"EUCAST. European committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. 2021. [cited 2021 Feb 01]. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_11.0_Breakpoint_Tables.pdf"},{"key":"cit0040","unstructured":"AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use. FDA. 2016. [cited 2021 Feb 01]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf"},{"key":"cit0041","unstructured":"European Medicines Agency. Zavicefta: summary of product characteristics. 2018. [cited 2021 Feb 01]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.010"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy492"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522"},{"issue":"3","key":"cit0051","doi-asserted-by":"crossref","first-page":"e02320","DOI":"10.1128\/AAC.02320-19","volume":"64","author":"Tsolaki V","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa503"},{"key":"cit0053","first-page":"ciab176","author":"Tumbarello M","year":"2021","journal-title":"Clin Infect Dis"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa651"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0851-9"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz354"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03517-y"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03553-8"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00573-18"},{"key":"cit0062","unstructured":"FDA (RECARBRIO) imipenem-cilastatin-relebactam injection. 2019. [cited 2021 Feb 01]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212819s000lbl.pdf"},{"key":"cit0063","unstructured":"EMA. Recarbrio (Imipenem-cilastatin-relebactam). Summary of Product Characteristics. 2020. [cited 2021 Feb 01]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S224228"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00472-17"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.08.004"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz497"},{"key":"cit0069","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/fmb-2020-0210","author":"Bassetti M","year":"2020","journal-title":"Future Microbiol"},{"key":"cit0070","first-page":"ciaa586","author":"Falcone M","year":"2020","journal-title":"Clin Infect Dis"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-19"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01432-20"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00682-18"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000600"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-19"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky522"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02229-19"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00579"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00575"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00020"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-15"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00711-16"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00567-17"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.02.021"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02048-18"},{"issue":"1","key":"cit0088","first-page":"e01904","volume":"62","author":"Hackel MA","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky251"},{"issue":"2","key":"cit0090","doi-asserted-by":"crossref","first-page":"e01951","DOI":"10.1128\/AAC.01951-19","volume":"64","author":"Castanheira M","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01936-19"},{"key":"cit0092","unstructured":"Vabomere\u00ae (meropenem\/vaborbactam for injection) [prescribing information]. U.S. Food and drug administration (FDA). 2017. [cited 2021 Feb 01]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf"},{"key":"cit0093","unstructured":"European Medicines Agency (EMA). Vaborem product information. 2018. [cited 2021 Feb 01]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaborem-epar-product-information_en.pdf"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1131"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa051"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02313-19"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01551-18"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01518"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa391"},{"key":"cit0102","volume-title":"29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","author":"Mendes P","year":"2019"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00130-20"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00552-20"},{"issue":"6","key":"cit0105","first-page":"e00212","volume":"64","author":"Lomovskaya O","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00757-20"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S205309"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00286-6"},{"key":"cit0110","unstructured":"EUCAST. Breakpoints for cefiderocol from EUCAST. 2020. [cited 2021 Feb 01]. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Cefiderocol_addendum_20200501.pdf"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01582-20"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz828"},{"key":"cit0114","unstructured":"FETROJA (cefiderocol) \u2013 U.S. food and drug administration (FDA). 2020. [cited 2021 Feb 01]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209445s002lbl.pdf"},{"key":"cit0115","unstructured":"Fetcroja (cefiderocol) | European medicines agency (EMA). 2020. [cited 2021 Feb 01]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-fetcroja_en.pdf"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"cit0119","first-page":"ciaa1799","author":"Naseer S","year":"2020","journal-title":"Clin Infect Dis"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01067-3"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"issue":"3","key":"cit0122","first-page":"e01699","volume":"64","author":"Morrissey I","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"cit0125","unstructured":"XERAVA (eravacycline) for injection \u2013 FDA. 2018. [cited 2021 Feb 01]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf"},{"key":"cit0126","unstructured":"XERAVA (eravacycline) - EMA. 2018. [cited 2021 Feb 01]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xerava"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02930-19"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3801-1"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky546"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02705-20"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00425"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38634-3"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2021.1935237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T18:12:23Z","timestamp":1642443143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2021.1935237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/14787210.2021.1935237"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2021.1935237","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}